ClinicalTrials.gg
Active, not recruitingNCT07180862Updated Sep 2, 2026

A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants

A Phase 1 interventional study of BAT3306 and US-Keytruda® in Carcinoma, Non-Small-Cell Lung, sponsored by Bio-Thera Solutions. Active, not recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by Bio-Thera Solutions · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China — 762 open to participants now, 987 under way, 202 of them phase 3. Carcinoma, Non-Small-Cell Lung · China.

Planned enrollment
590th of 1,595
160 · median 100
Started
2025
with 207 others
Phase 1
201 of 1,882
87 open now
Primary completion
2027-02
later than 508 of 986 live
Registered
1,609th of 1,882
by date

Among the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, this one is the 590th largest by planned enrollment of the 1,595 interventional ones that give a count, is one of 208 that started in 2025, is one of 201 in phase 1, reaches primary completion later than 508 of the 986 other live ones, and was the 1,609th registered.

Carcinoma, Non-Small-Cell Lung

7,635 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

762 of the 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China are open now. Recruiting first, the newest first:

757 more — sign in →

All 762 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,882 studies in Carcinoma, Non-Small-Cell Lung with a site in China, or all of them as a file.
02

Study summary

Comparing the PK similarity of BAT3306 and Keytruda; in NSCLC participants who were completely removed by surgery as an auxiliary treatment

Read the detailed description

This is a multicenter, randomized, double-blind, parallel-controlled, Phase 1 clinical study to evaluate the PK similarity of BAT3306 versus Keytruda® as adjuvant therapy in participants with early stage NSCLC. Participants must have no EGFR gene mutation or ALK gene rearrangement, have not received neoadjuvant or adjuvant radiotherapy and/or neoadjuvant chemotherapy, and have no plans for such treatment. A total of approximately 160 eligible participants will be randomly assigned in a 1:1 ratio to 2 double-blind treatment groups.

Participants who meet all inclusion criteria and none of exclusion criteria will be randomized in an Interactive Web Response System (IWRS).

All participants will receive the investigational medicinal product at 200 mg via intravenous infusion every 3 weeks for a treatment period of up to 12 months . Serum samples will be collected from participants at specified time points for PK analysis to evaluate the PK similarity and PK characteristics of BAT3306 versus Keytruda®, while also assessing their immunogenicity and safety, and preliminarily comparing their improvement in disease-free survival (DFS).

03

Conditions studied

  • Carcinoma, Non-Small-Cell Lung
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must meet all of the following criteria:

    1. Male or female, aged ≥18 and ≤75 years on the day of signing the Form (ICF);
    2. Participants are able to give voluntary informed consent and understand the study and are willing to follow and complete all the test procedures;
    3. confirmed non-small cell lung cancer (NSCLC) after surgery, with a clear histological type and a pathology report provided;

Exclusion criteria

Exclusion Criteria:

  • Participants who meet any of the following criteria will be excluded from the study:

    1. Presence of EGFR gene mutation;
    2. Pathological diagnosis of small cell lung cancer or mixed tumors with small cell components, large cell neuroendocrine carcinoma (LCNEC), or sarcomatoid tumors;
    3. Have previously received any of the following treatments:

      Have received > 4 cycles of chemotherapy. Prior neoadjuvant therapy. Major surgery within 4 weeks prior to randomization (including surgery for the primary neoplasm, but excluding vascular access procedures), or expected to undergo major surgery during the study.

      Use of Chinese herbal medicine with anti-tumor indications within 14 days prior to randomization.

      Use of growth factor support therapy or have received a transfusion within 14 days prior to randomization.

    4. Prior anti-tumor treatment with , anti-PD-L1/2, anti-CD137, CTLA-4 modulators, or any other immunomodulatory agents.
    5. Severe acute or chronic infection, including any active infection requiring systemic anti-infective therapy within 2 weeks prior to randomization;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    BAT3306

    Once every 3 weeks for a maximum of 1 year (not exceeding 18 cycles).

    Drug: BAT3306

  • Active comparator
    US-Keytruda® arm

    Once every 3 weeks for a maximum of 1 year (not exceeding 18 cycles).

    Drug: US-Keytruda®

Interventions

  • DrugBAT3306

    One vial of 4 mL of concentrate contains 100 mg of BAT3306

    Also known as: Pembrolizumab Injection

  • One vial of 4 mL of concentrate contains 100 mg of pembrolizumab

    Also known as: Pembrolizumab Injection

06

What researchers measure

Primary outcomes

  1. PK equivalence

    To compare the pharmacokinetic (PK) similarity of BAT3306 versus US-Keytruda® as adjuvant therapy in participants with completely resected NSCLC:AUC0-τ, ss

    Time frame: Cycle 1 day 1, day 2, day 3, day 5, day 8, day 15, day 22(each cycle is 21 days)

Secondary outcomes

  1. PK equivalence

    To evaluate the PK characteristics of BAT3306 and US-Keytruda® in participants with completely resected NSCLC:Cthough

    Time frame: Cycle 1,2,3,4,5,6,8,12,18(each cycle is 21 days)

  2. immunogenicity equivalence

    To evaluate the immunogenicity of BAT3306 and US-Keytruda® in participants with completely resected NSCLC:Anti-drug antibody (ADA) positive rate at Weeks 1, 4, 10, 16, 22,34,52

    Time frame: Weeks 1, 4, 10, 16, 22,34,52

  3. Vital signs

    Number of cases with abnormal vital signs results

    Time frame: The third week of every 4 cycles and EOT(No more than 18 cycles)(each cycle is 21 days)

  4. Physical examination

    Number of cases with abnormal Physical examination results

    Time frame: The third week of every 4 cycles and EOT(No more than 18 cycles)(each cycle is 21 days)

  5. Laboratory Examination

    Number of cases with abnormal Laboratory Examination results

    Time frame: The third and sixth weeks of every 4 cycles and EOT(No more than 18 cycles)(each cycle is 21 days)

  6. Adverse event

    Number of cases with all adverse medical events that occur after the subject receives the investigational drug assessed by CTCAE V5.0

    Time frame: The third week of every 4 cycles and EOT(No more than 18 cycles)(each cycle is 21 days)

  7. DFS(Disease-free survival)

    the duration of the absence of tumor recurrence or metastasis as per the RECIST 1.1 criteria.

    Time frame: Through study completion, No more than of 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's planned 16 months is below that.

Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 19, 2025
First posted
Sep 18, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Feb 28, 2027
CompletionEst.
Nov 30, 2027
Last update
Sep 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07180862
Responsible party
Sponsor
First posted
Sep 18, 2025
Start date
Oct 14, 2025
Primary completion
Feb 28, 2027 (estimated)
Completion
Nov 30, 2027 (estimated)
Last update
Sep 2, 2026

Study contacts

Xiaorong Dong, Dr.
principal investigator · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion